COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Affiliations

¹ Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA.
² Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA; Molecular, Cellular and Developmental Biology Program, Ohio State University, Columbus, OH 43210, USA.
³ Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
⁴ Comprehensive Cancer Center, James Cancer Hospital, Ohio State University, Columbus, OH 43210, USA.
⁵ Comprehensive Cancer Center, James Cancer Hospital, Ohio State University, Columbus, OH 43210, USA. Electronic address: Peter.Shields@osumc.edu.
⁶ Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address: Zihai.Li@osumc.edu.
⁷ Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA; Viruses and Emerging Pathogens Program, Infectious Diseases Institute, Ohio State University, Columbus, OH 43210, USA; Department of Microbial Infection and Immunity, Ohio State University, Columbus, OH 43210, USA. Electronic address: Liu.6244@osu.edu.

PMID: 34986328
PMCID: PMC8716174
DOI: 10.1016/j.ccell.2021.12.014

Comparative Study

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Cong Zeng et al. Cancer Cell. 2022.

. 2022 Feb 14;40(2):117-119.

doi: 10.1016/j.ccell.2021.12.014. Epub 2021 Dec 30.

Authors

Affiliations

¹ Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA.
² Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA; Molecular, Cellular and Developmental Biology Program, Ohio State University, Columbus, OH 43210, USA.
³ Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
⁴ Comprehensive Cancer Center, James Cancer Hospital, Ohio State University, Columbus, OH 43210, USA.
⁵ Comprehensive Cancer Center, James Cancer Hospital, Ohio State University, Columbus, OH 43210, USA. Electronic address: Peter.Shields@osumc.edu.
⁶ Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address: Zihai.Li@osumc.edu.
⁷ Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA; Viruses and Emerging Pathogens Program, Infectious Diseases Institute, Ohio State University, Columbus, OH 43210, USA; Department of Microbial Infection and Immunity, Ohio State University, Columbus, OH 43210, USA. Electronic address: Liu.6244@osu.edu.

PMID: 34986328
PMCID: PMC8716174
DOI: 10.1016/j.ccell.2021.12.014

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Comment in

SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate.
Rizzo A, Palmiotti G. Rizzo A, et al. Future Oncol. 2022 Apr;18(11):1301-1302. doi: 10.2217/fon-2022-0024. Epub 2022 Feb 3. Future Oncol. 2022. PMID: 35109688 Free PMC article. No abstract available.

References

1. Collier D.A., Ferreira I.A.T.M., Kotagiri P., Datir R.P., Lim E.Y., Touizer E., Meng B., Abdullahi A., Elmer A., Kingston N., et al. CITIID-NIHR BioResource COVID-19 Collaboration Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417–422. - PMC - PubMed
1. Greenberger L.M., Saltzman L.A., Senefeld J.W., Johnson P.W., DeGennaro L.J., Nichols G.L. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell. 2021;39:1297–1299. - PMC - PubMed
1. Karim S.S.A., Karim Q.A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398:2126–2128. - PMC - PubMed
1. Keehner J., Horton L.E., Binkin N.J., Laurent L.C., Pride D., Longhurst C.A., Abeles S.R., Torriani F.J., SEARCH Alliance Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N. Engl. J. Med. 2021;385:1330–1332. - PMC - PubMed
1. Shapiro L.C., Thakkar A., Campbell S.T., Forest S.K., Pradhan K., Gonzalez-Lugo J.D., Quinn R., Bhagat T.D., Choudhary G.S., McCort M., et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2021;40 S1535-6108(21)00606-1. - PMC - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Affiliations

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Authors

Affiliations

Conflict of interest statement

Comment in

References

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous